FTB (fractional tumor burden) is a quantitative perfusion-based biomarker that distinguishes high-grade brain tumor (including metastatic tumor) from non-tumor, on a voxel-wise basis.
Conventional imaging (T1+C) fails to provide this information. In fact, often treatment effect mimics tumor on T1+C images. FTB maps get more information from routine MRI exams.
Generating an FTB map is a fully automated process consisting of two unique steps.
1) IB’s proprietary Delta T1 mapping technology is used to identify true regions of contrast enhancement. Since IB Delta T1 maps are quantitative, consistent ROIs can be obtained (independent of scanner, field strength, patient, or timepoint) and used in the second step.
2) IB Neuro’s exclusive DSC perfusion platform computes quantitative blood volume (sRCBV) values which are then co-registered to the ROI obtained in step 1. These values are classified (based on user specification) to create a quantitative and intuitive map that clearly differentiates regions tumor vascularity (sRCBV).
Clinical utility has been demonstrated for initial diagnosis, biopsy guidance, and treatment prognostication and surveillance.
FTB maps reliable address the question “Is the enhancing region tumor or is it an effect due to treatment”. More importantly, the maps can be directly compared across time, showing accurate changes in classification volumes.
Some groups have conducted preliminary studies correlating FTB (expressed as a percentage) to Overall Survival (OS). If you are interested in collaborating with us on this initiative, please contact us!
Conventional Imaging (post contrast T1) used to monitor
GBM treatment response to gallium maltotate (GaM)
Imaging Biometrics FTB maps used to quantify GBM
treatment response
